Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:AUP NYSE:BHC TSE:ITH NASDAQ:SLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPAurinia PharmaceuticalsC$0.00C$11.77▼C$26.00C$2.15BN/A229,895 shs4.61 million shsBHCBausch Health Cos$5.06-2.0%$5.46$4.93▼$8.69$1.93B0.41.78 million shs1.85 million shsITHInternational Tower Hill MinesC$2.96+3.1%C$3.39C$1.14▼C$4.94C$774.45M2.11740380,395 shs57,497 shsSLSSELLAS Life Sciences Group$7.83+1.0%$6.30$1.39▼$9.51$1.52B2.510.00 million shs4.06 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPAurinia Pharmaceuticals0.00%0.00%0.00%0.00%0.00%BHCBausch Health Cos-1.94%-5.95%-3.99%+1.81%-5.07%ITHInternational Tower Hill Mines+3.14%+4.23%-22.31%-15.19%+133.07%SLSSELLAS Life Sciences Group+1.03%-4.86%+19.91%+45.81%+422.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPAurinia PharmaceuticalsC$0.00C$11.77▼C$26.00C$2.15BN/A229,895 shs4.61 million shsBHCBausch Health Cos$5.06-2.0%$5.46$4.93▼$8.69$1.93B0.41.78 million shs1.85 million shsITHInternational Tower Hill MinesC$2.96+3.1%C$3.39C$1.14▼C$4.94C$774.45M2.11740380,395 shs57,497 shsSLSSELLAS Life Sciences Group$7.83+1.0%$6.30$1.39▼$9.51$1.52B2.510.00 million shs4.06 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPAurinia Pharmaceuticals0.00%0.00%0.00%0.00%0.00%BHCBausch Health Cos-1.94%-5.95%-3.99%+1.81%-5.07%ITHInternational Tower Hill Mines+3.14%+4.23%-22.31%-15.19%+133.07%SLSSELLAS Life Sciences Group+1.03%-4.86%+19.91%+45.81%+422.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPAurinia Pharmaceuticals 0.00N/AN/AN/ABHCBausch Health Cos 1.80Reduce$8.0058.26% UpsideITHInternational Tower Hill Mines 0.00N/AN/AN/ASLSSELLAS Life Sciences Group 2.00Hold$10.0027.71% UpsideCurrent Analyst Ratings BreakdownLatest ITH, BHC, AUP, and SLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026BHCBausch Health Cos Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)4/27/2026BHCBausch Health Cos Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Perform$10.00 ➝ $9.004/21/2026SLSSELLAS Life Sciences Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPAurinia PharmaceuticalsC$57.59M0.00N/A6.75C$2.59 per share0.00BHCBausch Health Cos$10.27B0.18$7.12 per share0.71$1.02 per share4.96ITHInternational Tower Hill MinesN/AN/AC$0.13 per share22.50C$0.69 per shareN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/A$0.46 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPAurinia PharmaceuticalsN/A-C$1.48N/AN/AN/AN/AN/AN/AN/ABHCBausch Health Cos$157M-$3.24N/A1.34N/A-11.47%-2,922.77%5.63%7/29/2026 (Estimated)ITHInternational Tower Hill Mines-C$2.36M-C$0.01N/AN/AN/AN/A-2.04%-3.65%N/ASLSSELLAS Life Sciences Group-$26.86M-$0.23N/AN/AN/AN/A-47.12%-42.63%8/11/2026 (Estimated)Latest ITH, BHC, AUP, and SLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026SLSSELLAS Life Sciences Group-$0.06-$0.05+$0.01-$0.05N/AN/A5/8/2026Q1 2026ITHInternational Tower Hill MinesN/AC$0.01N/AC$0.01N/AN/A4/29/2026Q1 2026BHCBausch Health Cos$0.81$0.78-$0.03-$3.76$2.37 billion$2.46 billion3/19/2026Q4 2025SLSSELLAS Life Sciences Group-$0.0633-$0.05+$0.0133-$0.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAUPAurinia PharmaceuticalsN/AN/AN/AN/AN/ABHCBausch Health CosN/AN/AN/AN/AN/AITHInternational Tower Hill MinesN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPAurinia Pharmaceuticals2.6911.9311.02BHCBausch Health Cos54.681.320.97ITHInternational Tower Hill MinesN/A238.0330.48SLSSELLAS Life Sciences GroupN/A17.2217.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPAurinia PharmaceuticalsN/ABHCBausch Health Cos78.65%ITHInternational Tower Hill Mines9.12%SLSSELLAS Life Sciences Group17.38%Insider OwnershipCompanyInsider OwnershipAUPAurinia PharmaceuticalsN/ABHCBausch Health Cos20.67%ITHInternational Tower Hill Mines0.51%SLSSELLAS Life Sciences Group1.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPAurinia Pharmaceuticals300128.40 millionN/ANot OptionableBHCBausch Health Cos20,300374.02 million296.71 millionOptionableITHInternational Tower Hill Mines220261.64 millionN/ANot OptionableSLSSELLAS Life Sciences Group10196.63 million194.08 millionNot OptionableITH, BHC, AUP, and SLS HeadlinesRecent News About These CompaniesSLS Stock Slides Premarket: Traders Brace For Key Arbitration Ruling In GPS China Payment DisputeJune 5, 2026 | finance.yahoo.comAnalyzing SELLAS Life Sciences Group (NASDAQ:SLS) and Exelixis (NASDAQ:EXEL)June 4, 2026 | americanbankingnews.comSELLAS Life Sciences boosts liquidity through warrant exercisesJune 2, 2026 | tipranks.comJim Cramer on SELLAS: “It’s a Great Spec”June 1, 2026 | insidermonkey.comSELLAS Life Sciences Group (SLS) Is Up 21.4% After REGAL Nears Topline Readout And Cramer EndorsementMay 30, 2026 | finance.yahoo.comSLS Stock Extends Rally Overnight: CEO Says ‘Bullish’ Leukemia Data Could Drive NCCN Recognition For GPSMay 28, 2026 | finance.yahoo.comSellas Life Sciences: The Internal Inconsistency Of An Assumed Positive REGAL ReadoutMay 28, 2026 | seekingalpha.comSLS stock surges toward fifth weekly rise: CEO touts GPS as lifeline for elderly patients as cancer summit loomsMay 27, 2026 | msn.comSLS Stock Heads For Its Best Month This Year Ahead Of Key AML Trial ReadoutMay 26, 2026 | finance.yahoo.comSLS stock heads for their best month this year ahead of key AML trial readoutMay 26, 2026 | msn.comSellas Life Sciences: REGAL Delay May Be A Warning Sign, Not A Bullish SignalMay 22, 2026 | seekingalpha.comSLS stock jumps premarket: CEO says GPS AML data has ‘very good chance’ to beat earlier survival outcomesMay 20, 2026 | msn.comSELLAS Life Sciences Stock Is Surging Wednesday: What's Driving The Move?May 20, 2026 | benzinga.comSELLAS Life Sciences Stock Is Surging Wednesday: What's Driving The Move?May 20, 2026 | benzinga.comSLS stock rallies after hours as CEO teases leukemia study data any day nowMay 19, 2026 | msn.comSELLAS Life Sciences (SLS) Is Up 50.5% After Pivotal AML Trial Nears Readout And Adds Funding Flexibility – Has The Bull Case Changed?May 16, 2026 | uk.finance.yahoo.comSLS stock hits 4-year high: BlackRock stake boost fuels buzz around looming AML trial readoutMay 14, 2026 | msn.comSELLAS Life Sciences to Participate in Upcoming Investor ConferencesMay 14, 2026 | globenewswire.comSLS on track to clock best week in over 4 months: Retail divided between stock drop or multibagger status amid upcoming leukemia trial readoutMay 13, 2026 | msn.comSELLAS rises as Q1 update suggests lead program nears final analysisMay 13, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 2026Will the SpaceX IPO Put These 5 Public Space Stocks Into a Higher Orbit?By Ryan Hasson | June 2, 20263 Stocks to Own If Gas Prices Keep RisingBy Dan Schmidt | May 16, 20263 Up-and-Coming Stocks That Could Be the Next NVIDIABy Chris Markoch | June 1, 2026ITH, BHC, AUP, and SLS Company DescriptionsAurinia Pharmaceuticals TSE:AUPAurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.Bausch Health Cos NYSE:BHC$5.06 -0.11 (-2.03%) Closing price 06/12/2026 03:59 PM EasternExtended Trading$5.06 +0.00 (+0.10%) As of 06/12/2026 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.International Tower Hill Mines TSE:ITHC$2.96 +0.09 (+3.14%) As of 06/12/2026 04:00 PM EasternInternational Tower Hill Mines Ltd. has a 100% interest in its Livengood Gold Project located along the paved Elliott Highway, 70 miles north of Fairbanks, Alaska.SELLAS Life Sciences Group NASDAQ:SLS$7.83 +0.08 (+1.03%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$7.94 +0.11 (+1.46%) As of 06/12/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
